多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究

目的  探讨miR-21通过靶向作用自噬相关靶基因5（Atg5）调控非小细胞肺癌（NSCLC）自噬的作用机制及其在A549细胞增殖、迁移及侵袭中的作用。方法  无义核酸序列NC（NC组）、miR-21 模拟物（miR-21 mimics组）、miR-21抑制物（miR-21 抑制组）分别转染A549细胞, CCK-8检测细胞增殖情况;划痕实验检测细胞迁移能力; Transwell侵袭实验检测细胞侵袭能力。双荧光素酶报告实验验证miR-21和Atg5之间的靶向关系。Western blotting检测LC3B-II、p62和Atg5蛋白的表达。结果  与NC组比较,miR-21 mimics组细胞增殖、迁移、侵袭能力均上调,miR-21 抑制组细胞增殖、迁移、侵袭能力均下调（P＜0.05）。双荧光素酶报告实验结果显示,miR-21显著抑制野生型Atg5 3’-UTR质粒转染细胞的荧光素酶活性（P＜0.05）,但对突变型Atg5 3’-UTR的基因报告质粒与miR-21 mimics共转染之后,并未对荧光素酶活性产生影响。NC组LC3B-II蛋白表达量为1.24±0.059,低于miR-21 mimics组的1.98±0.077,高于miR-21抑制组的0.52±0.021（P＜0.05）;NC组p62蛋白表达量为0.62±0.021,高于miR-21 mimics组的0.45±0.020,低于miR-21抑制组的0.79±0.031（P＜0.05）;NC组Atg5蛋白表达量为1.17±0.025,高于miR-21 mimics组的0.38±0.014,低于miR-21抑制组的1.40±0.039（P＜0.05）。与NC组比较, 3-MA处理降低miR-21 mimics转染诱导的A549细胞增殖能力（P＜0.05）;划痕实验和Transwell实验表明,3-MA处理抑制了miR-21mimics转染诱导的A549细胞的迁移和侵袭,差异有统计学意义（P＜0.05）。结论  miR-21靶向Atg5调控NSCLC自噬促进细胞增殖、迁移和侵袭。     

吉西他滨与奥沙利铂联合化疗治疗晚期膀胱癌的疗效和不良反应

[目的]探讨吉西他滨联合奥沙利铂方案治疗晚期膀胱癌的疗效及不良反应。[方法]56例Ⅳ期膀胱癌接受吉西他滨联合奥沙利铂方案化疗:吉西他滨1000mg/m2,d1和d8,奥沙利铂135mg/m2,d1;21d为1个周期,每2疗程评价疗效。[结果]本组65例晚期膀胱癌患者完全缓解(CR)3例(5.36%),部分缓解(PR)27例(48.21%),总有效率(CR+PR)43.57%。在疼痛缓解、全身情况明显改善,生存质量和KPS评分提高等方面均取得了较好疗效。主要不良反应为骨髓抑制、外周神经毒性、消化道反应等。无治疗相关死亡者。[结论]吉西他滨与奥沙利铂联合化疗是治疗晚期膀胱癌的有效方法,并且毒副反应相对较轻。     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

中药泡洗治疗外伤性小儿跟腱部皮肤缺损16例

目的:观察中药泡洗对外伤性小儿跟腱部皮肤缺损的修复疗效.方法:中药煎成汤剂后,置于熏洗桶中,恒温于40 ℃,患足直接泡于中药药液中,浸泡60-90 min,2-3次/d.结果:3-13周内,缺损皮肤全部愈合,无感染及手术植皮病例.结论:对小儿跟腱部皮肤缺损的修复,中药汤剂泡洗方法简便有效.     

多西他赛或奥沙利铂联合卡培他滨治疗老年晚期胃癌疗效及并发症比较

Objective To compare the short-term efficacy and adverse effects of docetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients. Methods Eighty-two aged patients with late-staged gastric cancer were randomly divided into two groups,of which 38 patients were treated group) ,and 44 patients were treated with oxaliplatin (100 mg/m2 ivgtt on 1st day) and eapecitabine (2000 mg/1 cycle). Results There is no failure of follow-up. In the docetaxe group,the effective rate was 52.63% (20/38) and 54.55 % (24/44) for the docetaxe and oxaliplatin group,respectively (P>0.05). The median progression-free survival(PFS) in the docetaxe group (6.1 months) was similar to that in the oxaliplatin group (6.3 months) (P>0.05). Gastrointestinal response,myelosuppression and neurotoxicity (Ⅰ or Ⅱ level) were the most common ad-verse effects observed in both groups (P>0.05). No chemotherapy-related death was observed. Conclusions The short-term efficacy of decetaxe or oxaliplatin combined with capecitabine in the treatment of late-staged gastric cancer in aged patients is similar,and the adverse effects are all within tolerance limits.     

人宫颈癌移植瘤照射过程中氧分压变化规律的研究

目的研究人宫颈癌移植瘤照射过程中氧分压变化规律。方法人宫颈癌HeLa细胞培养后接种于裸小鼠右后大腿外侧皮下,每鼠02ml。待肿瘤长至直径15cm以上时,用10MeV电子线照射裸鼠移植瘤及正常后腿,SSD为96cm,吸收剂量率为100Gymin,总吸收剂量400cGy。用极谱法测定裸鼠移植瘤及正常后腿氧分压,照射前及照射过程中每30秒分别记录肿瘤及正常组织的氧分压读数,持续至放疗后4min。结果①8只裸鼠,7只成活,其中7只成瘤,成瘤率875%(78)。瘤体平均(17585±02020)cm。②照射前移植瘤乏氧状况测定,瘤体平均氧分压(37857±06694)kPa,而正常后腿对照氧分压(117714±22787)kPa,二者差异有统计学意义(t=7678,P<001)。③正常组织照射中的氧分压与照射时间无关,r=0029,P=0940;肿瘤组织照射中的氧分压随照射时间的增加而降低,相关系数r=0927,P<0001;正常组织照射后的氧分压与照射时间无关,r=0446,P=0229;肿瘤组织照射后的氧分压随照射时间的增加而降低,r=0964,P<0001;肿瘤组织照射后的氧分压与照射前的氧分压相关,r=0993,P<0001。④肿瘤组织照射后的氧分压与照射前的氧分压相关,r=0993,P<0001。结论照射过程中移植瘤氧分压呈下降趋势,放疗后数分钟仍然持续下降。